Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers

Clare F. Malone¹,², Jody A. Fromm¹,², Ophélia Maertens¹,², Thomas DeRaedt¹,²,³, Rachel Ingraham¹,², Karen Cichowski¹,²,³

C.F. Malone and J. Fromm are co-first authors who contributed equally to this work.

Authors’s Affiliations: ¹Genetics Division, Department of Medicine, Brigham and Women’s Hospital, Boston MA 02115 ²Harvard Medical School, Boston MA 02115, ³Ludwig Center at Dana-Farber/Harvard Cancer Center, Boston, MA 02115

Running Title: Targets, therapies and biomarkers for NF1-mutant tumors

Keywords: NF1, RAS, mouse models, targeted therapies, MEK, PI3K, mTOR

Financial support: KC and this work were supported by a grant from the NCI (5R01CA111754-08) the Department of Defense (W81XWH-13-1-0044), the Children’s Tumor Foundation (CTF), and the Ludwig Center at DF/HCC. CM was supported in part by the Pharmacological Sciences Training Program Grant from the National Institute of Health (T32 GM007306). JF was supported by the CTF.
Corresponding Author: Karen Cichowski, Brigham & Women’s Hospital, 77 Avenue Louis Pasteur, NRB 0458C, Boston MA 02115. Phone: 617-525-4722; E-mail:
kcichowski@rics.bwh.harvard.edu

There are no conflicts of interest to disclose.
**ABSTRACT**

*NF1* encodes a RAS GTPase-Activating Protein. Accordingly, aberrant RAS activation underlies the pathogenesis of *NF1*-mutant cancers. Nevertheless, it is unclear which RAS pathway components represent optimal therapeutic targets. Here we identify mTORC1 as the key PI3K effector in *NF1*-mutant nervous system malignancies and conversely show that mTORC2 and AKT are dispensable. However, we find that tumor regression requires sustained inhibition of both mTORC1 and MEK. Transcriptional profiling studies were therefore used to establish a signature of effective mTORC1/MEK inhibition *in vivo*. We unexpectedly found that the glucose transporter, GLUT1, was potently suppressed but only when both pathways were inhibited. Moreover, unlike *VHL* and *LKB1* mutant cancers, reduction of $^{18}$F-FDG uptake required the suppression of both mTORC1 and MEK. Together these studies identify optimal and sub-optimal therapeutic targets in *NF1*-mutant malignancies and define a non-invasive means of measuring combined mTORC1/MEK inhibition *in vivo*, which can be readily incorporated into clinical trials.

**SIGNIFICANCE**

This work demonstrates that mTORC1 and MEK are key therapeutic targets in *NF1*-mutant cancers and establishes a non-invasive biomarker of effective, combined target inhibition that can be evaluated in clinical trials.
INTRODUCTION

The *NF1* tumor suppressor is mutated or suppressed in a variety of sporadic cancers including glioblastoma, neuroblastoma, melanoma and non-small cell lung cancer (1-5). *NF1* mutations also underlie the familial cancer syndrome, neurofibromatosis type 1 (NF1) (6,7). NF1 patients exhibit a variety of tumorigenic and non-tumorigenic manifestations but the most common cause of death is malignant peripheral nerve sheath tumors (MPNSTs). These highly aggressive tumors are lethal in approximately 70% of patients, and conventional chemotherapy and radiation do not reduce mortality in individuals with inoperable tumors (8-10). Therefore, developing effective targeted therapies for these individuals represents an important and unmet clinical need. Moreover, an effective therapy for this tumor type may be more broadly applicable to other sporadic *NF1*-mutant cancers.

The *NF1* tumor suppressor gene encodes a RAS GAP, which inactivates RAS by catalyzing the hydrolysis of RAS-GTP (6,7). As such, when *NF1* is mutated or suppressed, RAS and downstream effectors become hyperactivated (11). Both the PI3K/mTOR and MEK/ERK pathways have been shown to be important in various *NF1*-mutant tumors and therefore components of these pathways represent potential therapeutic targets (12-15). However, given the plethora of available drugs that target these pathways we set out to genetically and chemically deconstruct the most important signaling nodes in *NF1*-mutant MPNSTs. Together with preclinical studies in a genetically engineered mouse tumor model, we found that mTORC1 is the key PI3K pathway component in these *NF1*-mutant malignancies, AKT and TORC2 are
dispensable, and only sustained mTORC1 and MEK inhibition promotes tumor regression.

Several combined PI3K/MEK pathway trials are in development or are being considered for other cancers (16). However, the clinical challenge will be to identify a drug combination and dose that effectively suppresses both pathways, while minimizing toxicity. It is currently unclear how dosing can be adjusted while confirming that both targets are sufficiently inhibited in real time, especially given that the duration of inhibition appears to be an important determinant of efficacy. Thus, establishing a tractable biomarker for effective, combined target inhibition would greatly facilitate this effort. By performing transcriptional profiling and imaging studies we unexpectedly identified GLUT1, which mediates $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG) uptake, as a key gene that is suppressed prior to tumor regression but only when both pathways are effectively inhibited. Moreover, we show that $^{18}$F-FDG uptake is a reliable readout of combined target inhibition. This insight can be directly applied to the design of clinical trials in NF1 mutant cancers and may also have broader utility in other RAS-driven tumors.

RESULTS

p110α and mTORC1 are the key effectors in NF1-mutant nervous system malignancies
We previously showed that loss or inactivation of \textit{NF1} triggers the aberrant activation of PI3K/mTORC1 signaling in human and mouse MPNSTs (17). However, it is currently unclear which specific components within this pathway represent the best therapeutic targets. Such insight would reveal which drugs should be preferentially evaluated or excluded in clinical trials. Therefore, we sought to genetically and chemically deconstruct this pathway in \textit{NF1}-mutant MPNSTs. There are three Class 1A catalytic PI3K isoforms: p110\(\alpha\), p110\(\beta\), and p110\(\delta\). While p110\(\alpha\) is frequently mutated in human cancer, p110\(\beta\) has been shown to play an essential role in \textit{PTEN} mutant cancers and p110\(\delta\) is critical in chronic lymphocytic leukemia (18-20). To identify which catalytic isoform(s) are essential in \textit{NF1}-deficient cancers, we first assessed the biological effects of isoform-specific ablation in human MPNST cells derived from NF1 patients. While all three isoforms were present in MPNSTs, genetic ablation of p110\(\alpha\), but not p110\(\beta\) or p110\(\delta\), dramatically impaired the proliferation of both tumor lines (Fig 1A). Similarly, \textit{NF1}-mutant GBMs were exclusively sensitive to siRNA-mediated depletion of p110\(\alpha\), but not p110\(\beta\) or p110\(\delta\), suggesting that p110\(\alpha\) may play a more general role in \textit{NF1}-deficient cancers (Fig 1A). To complement these findings, we utilized PI3K isoform-specific inhibitors: the p110\(\alpha\)-specific inhibitor A66-(S), the p110\(\beta\)-specific inhibitor AZD-6284, and the p110\(\delta\)-specific inhibitor CAL-101, as well as GDC-0941, a pan-PI3K inhibitor (21-24). The reported specificities of each drug are outlined in Supplementary Table S1. In human MPNST cell lines, the p110\(\alpha\)-specific inhibitor A66-(S) and GDC-0941 potently inhibited the phosphorylation of AKT and S6; however, the p110\(\beta\)- or p110\(\delta\)-specific inhibitors, AZD-6284 and CAL-101 respectively, did not suppress the phosphorylation of either protein (Fig 1B). Accordingly, A66-(S) was the
only isoform-specific inhibitor that suppressed proliferation in these cells (Fig 1C; p=0.039 in 90-8TLs and p=0.0006 in S462s). Together, these observations suggest that p110α is the primary catalytic subunit responsible for pro-proliferative PI3K signaling in NF1-mutant nervous system malignancies.

mTOR functions in two distinct complexes: the rapamycin-sensitive complex mTORC1, which phosphorylates 4E-BP1 and S6 kinase, and the relatively rapamycin-insensitive complex mTORC2, which phosphorylates AKT at serine 473 (25,26). NF1-deficient MPNSTs have been shown to be sensitive to rapamycin, indicating that mTORC1 plays a role in this tumor type; however, the contribution of mTORC2 activity, if any, to MPNST growth is unknown (13,17). We genetically targeted essential component proteins of each complex in order to evaluate the relative contribution of these two complexes. RAPTOR, is an essential component of mTORC1, but is not present in mTORC2, while RICTOR, a primary component protein of mTORC2, is not a member of the mTORC1 complex (27,28) As expected, siRNA-mediated-loss of RAPTOR or mTOR suppressed S6 phosphorylation and led to impaired proliferation of MPNST cell lines (Fig 1D). However, loss of RICTOR had no effect on MPNST proliferation, despite the effective suppression of phosphorylation of the mTORC2 target AKT (Fig 1D).

To further evaluate a role for AKT, or lack thereof, tumors cells were treated with the allosteric AKT inhibitor MK-2206 (29). MK-2206 suppressed the phosphorylation of AKT at S473 and T308, and effectively inhibited AKT kinase activity as confirmed by the loss of TSC2 phosphorylation on T1462 (Fig 1E and Supp Fig. S1). However, unlike
rapamycin, MK-2206 had no effect on the proliferation of NF1-mutant MPNST cells (Fig 1E). The mTOR kinase inhibitor Torin1 inhibits both the mTORC1 and mTORC2 complexes. Notably, Torin1 has been reported to more effectively inhibit mTORC1, as compared to rapamycin, and in particular more potently suppresses 4E-BP1 phosphorylation, as observed in these studies (Fig 1E and Supp Fig. S1). Accordingly, Torin1 potently suppressed the proliferation of NF1 mutant cells and did so better than rapamycin (p< 0.02). As noted, both MK-2206 and Torin1 equivalently and potently suppressed AKT phosphorylation and activity, although only Torin1 suppressed MPNST cell proliferation. Moreover, MK-2206 did not enhance the anti-proliferative effects of rapamycin (Fig 1F). Taken together, these results suggest that mTORC1 is a critical effector in NF1-mutant cancers and that mTORC2 and AKT are dispensable in these tumor cells.

**Selection of an effective PI3K/mTOR pathway inhibitor**

These *in vitro* studies suggested that pan-PI3K inhibitors, p110α-specific inhibitors or mTORC1 inhibitors should suppress the growth of NF1-mutant MPNSTs. Therefore, we first evaluated the *in vivo* effects of GDC-0941 and rapamycin in a genetically engineered mouse MPNST model. Like human MPNSTs, tumors from these animals harbor compound mutations in Nf1 and p53, and develop with an average latency of five months. These MPNSTs are highly aggressive, and mice survive for an average of 10.7 days after tumors are detected, thus recapitulating the aggressive nature of human tumors (30). As previously shown, rapamycin suppressed the growth of Nf1/p53 mutant MPNSTs (p<0.0001) (13); however, GDC-0941 did so significantly less well (p=0.0021) (Fig 2A).
Notably, the maximum tolerated dose of GDC-0941 (150mg/kg) inhibited the phosphorylation of AKT, S6 and 4E-BP1 in tumors within 1 hour, however these pathways were reactivated within 4 hours after treatment (Fig 2B). In contrast, rapamycin suppressed S6 and 4E-BP1 phosphorylation for at least 18 hours, consistent with the observed enhanced efficacy and the demonstrated importance of mTORC1 in these tumors. It should be noted that AKT is not activated by relief of feedback mechanisms in this model, as we have previously shown (Fig 2B) (13,31). Several other PI3K/mTOR pathway inhibitors including BEZ-235, Torin2, and INK-128 were evaluated in these animals (data not shown); however we were unable to identify an inhibitor that exhibited better pharmacodynamics or growth inhibition than rapamycin at tolerable doses in these animals. Therefore, rapamycin was selected for further studies.

**Combined, sustained inhibition of mTORC1 and MEK promote MPNST regression in vivo**

Although mTORC1 is a critical signaling node in *NF1* mutant tumors, mTORC1 inhibition exerted only cytostatic effects on MPNSTs *in vitro* and *in vivo* (Fig 1D, E, 2A) (13). Therefore, we evaluated the effects of rapamycin combined with a MEK inhibitor, which targets a second critical RAS effector pathway inhibitor. Tumor-bearing mice were treated with vehicle, the MEK inhibitor PD-0325901, rapamycin, or the combination of rapamycin and PD-0325901. As a monotherapy, PD-0325901 slightly attenuated the growth of MPNSTs, but did so less than rapamycin (Fig 2C). However, combined PD-0325901 and rapamycin induced tumor regression in these mice (Fig 2C). Interestingly, these observations differ from effects observed in benign *NF1*-deficient peripheral
nervous system tumors and myeloid malignancies, where MEK appears to function as the dominant RAS-effector pathway and MEK inhibitors exert cytotoxic effects alone, suggesting that different tumor types harboring the same initial driving genetic lesion may rely on different downstream signals (32,33). Nevertheless, upon examining the pharmacodynamics of PD-0325901 at this dose, we found that ERK phosphorylation was inhibited for only 4-6 hours, whereas sustained inhibition could be achieved by dosing with PD-0325901 twice daily (Fig 2D). As such, we hypothesized that a revised dosing schedule might exert more potent therapeutic effects. Twice-daily PD-0325901 treatment did not promote tumor regression as a monotherapy, however when combined with rapamycin, twice daily PD-0325901 treatment improved the therapeutic response (Fig. 2E). All mice treated with this combination responded, and more than half of the tumors regressed 50% or more, with several shrinking 75% or more. Together, these observations indicate that the duration of both MEK and mTORC1 inhibition is a critical determinant of the therapeutic response.

**Identifying GLUT1 as a component of the therapeutic signature that is suppressed prior to tumor regression**

Pharmacodynamic markers in tumors are often not examined during clinical trials, and when they are, the kinetics of suppression are difficult to evaluate. Therefore, if a treatment does not show efficacy, especially in cases of dose de-escalation, it is often unclear whether the target or targets were sufficiently inhibited. Therefore, we sought to identify a molecular change that might serve as a functional biomarker of effective, combined inhibition of mTORC1 and MEK pathways. The transcriptional profiles of
tumors from animals treated with vehicle, rapamycin, PD-0325901 (twice daily), or the combination of rapamycin and PD-0325901 were evaluated. Importantly, tissues were collected after 14 hours of treatment: a time point that would capture transcriptional changes caused by sustained target inhibition but occurring prior to tumor regression. Using a gene expression class comparison, we identified a gene set that was exclusively regulated by combined rapamycin and PD-0325901 treatment (Fig 3A). Interestingly, Slc2a1, which encodes a glucose transporter and is commonly referred to as Glut1, was identified as one of the uniquely suppressed genes in rapamycin/PD901 treated tumors (Fig 3A). Effective mTORC1 and MEK target inhibition in tumor tissue was verified (Fig 3B). Q-PCR analysis confirmed that Glut1 levels were reduced 64% after only 14 hours of treatment compared to vehicle treated tumors and that neither rapamycin nor PD-0325901 exerted suppressive effects alone (Fig 3C). A dramatic decrease in GLUT1 protein levels was further confirmed by evaluating its expression in tumor biopsies taken before and 3 days after treatment (Fig 3D). These findings differ from observations in VHL and LKB1 mutant tumors, where GLUT1 mRNA and consequently protein expression is primarily regulated by mTOR and HIF1α, and its expression can be suppressed by mTORC1 inhibitors alone (34,35). However in these Nf1-mutant MPNSTs, suppression of both mTORC1 and the MEK/ERK pathways are required. This finding resolves a longstanding observation that rapamycin is not sufficient to suppress the expression of GLUT1, or other HIF-1α target genes in vitro or in vivo in this tumor type (13). Together, these results demonstrate that GLUT1 is suppressed in MPNSTs only after combined mTORC1 and MEK inhibition, which could be exploited for developing an imaging biomarker of combined target inhibition.
Only combined, effective suppression of mTORC1 and MEK inhibit $^{18}\text{F}-\text{FDG}$ uptake

GLUT1 is a membrane bound glucose transporter that is frequently over-expressed in tumors, in part, because altered tumor metabolism requires increased glucose uptake (36-39). This metabolic activity can be measured by positron emission tomography (PET) scans designed to quantify $^{18}\text{F}-\text{FDG}$ uptake (40). GLUT1 has been shown to regulate $^{18}\text{F}-\text{FDG}$ uptake in a variety of tumor types (41,42). MPNSTs are generally FDG-PET positive, and enhanced $^{18}\text{F}-\text{FDG}$ uptake is used to diagnose a conversion to malignancy, as MPNSTs often arise from benign precursor lesions (43). Because human MPNSTs exhibit a strong FDG-PET signal, and because GLUT1 was specifically suppressed in tumors treated with combined rapamycin and PD-0325901, we hypothesized that the substantial reduction in GLUT1 mRNA and protein might inhibit $^{18}\text{F}-\text{FDG}$ uptake in these tumors. To evaluate this possibility, FDG-PET imaging was performed on tumor bearing mice. As expected, MPNSTs were FDG-PET positive at baseline, mirroring the behavior of human MPNSTs (Fig 4A). Mice were then treated with vehicle, PD-0325901, rapamycin or PD-0325901/rapamycin and PET analysis was performed a second time, 40 hours after the baseline scan. This time point was selected because it represents a time before detectable regression occurs, in order to avoid any confounding change in the FDG-PET signal due to a reduction in tumor size. It should be noted that the initial (64%) decrease in Glut1 mRNA levels can be detected 14 hours after treatment, however given the dramatic decrease in GLUT1 protein after 72 hours this repression is sustained and perhaps enhanced, Animals treated with vehicle, PD-0325901,
or rapamycin, did not have a significant change in $^{18}$F-FDG uptake after treatment (Fig 4A,B); however, animals treated with both PD-0325901 and rapamycin exhibited a significant decrease in SUVmax values ($p<0.004$) (Fig 4A,B). Importantly, while hexokinase and other GLUT genes can regulate glucose uptake in some settings (41,44-46), rapamycin/PD-0325901 treatment did not affect the expression of any of these genes suggesting that GLUT1 may be the rate limiting step for FDG-PET uptake in MPNSTs (Supplemental Table S2).

These observations suggested that FDG-PET imaging could be used as a biomarker of effective combined mTORC1/MEK inhibition in $NF1$-mutant tumors. Such a biomarker would be invaluable in the course of evaluating similar therapies in the clinic and in the course of dose de-escalation/escalation studies. This biomarker would be particularly useful if the early change in FDG-PET imaging were predictive of a later change in tumor size. To experimentally evaluate this possibility, we performed a dose de-escalation study in mice. Mice were treated with rapamycin in combination with 100%, 50%, or 25% of the PD-0325901 dose. As expected, this produced a range of responses in FDG-PET uptake at 40 hours and tumor regression after 10 days (Fig. 4C,D). Importantly, the suppression of FDG-PET activity at 40 hours, as measured by change in SUVmax, correlated with the ultimate decrease in tumor size after 10 days (Pearson R=0.711, $p=0.03$) (Fig 4D,E). These results suggest that early changes in the FDG-PET signal are indicative of the degree of target inhibition and correlate with eventual tumor regression in MPNSTs treated with combined mTORC1/MEK inhibitors.
DISCUSSION

Numerous PI3K pathway inhibitors have been developed and are being evaluated in clinical trials (16). However in many cancers it is not clear which specific component(s) within this pathway are most critical or to what degree they must be inhibited. Such information would undoubtedly facilitate the selection of the most appropriate drugs for clinical studies. In this study we used a genetic and chemical approach to systematically deconstruct the PI3K signaling pathway in NF1-mutant nervous system malignancies. Importantly, we found that mTORC1, which is regulated by p110α in these tumors, is the minimal, essential PI3K pathway component and that surprisingly AKT and mTORC2 are dispensable. However, while agents that inhibit mTORC1 promote cytostasis in human tumor cells and genetically engineered models, tumor regression requires concomitant suppression of the MEK/ERK pathway.

Notably, there are currently no effective therapies for MPNSTs. As such, these studies reveal a promising therapeutic approach as well as a mechanistic framework for selecting the most appropriate agents for clinical trials. For example, because p110β does not appear to contribute to the therapeutic response in these tumors perhaps p110α-specific, β-sparing PI3K inhibitors could be used with less toxicity (47). Alternatively, because mTORC1 appears to be the key PI3K effector in these tumors perhaps rapalogues, which exhibit excellent pharmacokinetic properties, may be suitable for combination therapies. The observation that AKT is not activated in these tumors by feedback inhibition and that AKT inhibitors do not enhance the effects of rapamycin, further alleviates the concern that AKT suppression may be required in this setting. Nevertheless, these studies suggest
that successful agents must promote sustained inhibition of both ERK and mTORC1. Importantly, suppression of these same targets results in tumor regression in a mouse model of NF1-mutant melanoma, underscoring the importance of these pathways in NF1-deficient cancers (4). Nevertheless, establishing the sufficient degree/length of inhibition of both targets that will be required to mediate an efficacious response in patients represents a formidable challenge.

While mouse models are useful for identifying critical therapeutic targets in genetically defined cancers, the ultimate success of a therapy in humans depends on many factors. Certainly, species-specific differences in tumor complexity may limit efficacy or restrict therapeutic responses to a subset of patients. However, perhaps an even more important consideration relates to dosing. One of the primary obstacles in developing combination therapies, especially when targeting two major signaling pathways, is achieving efficacy while preventing toxicity. As such, even if the correct therapeutic targets have been identified, it may not be possible to sufficiently suppress these targets in humans. MEK inhibitors have been shown to exhibit toxicity in humans at high doses (48,49). Therefore in this study we used a dose of PD-0325901 that is comparable to the tolerable dose in humans. Similarly, the dose of rapamycin was selected based on a previous preclinical study that led to successful human clinical trial in a number of tuberous sclerosis complex related pathologies, although reported trough plasma levels were somewhat higher than what has been observed in humans (~50ng/ml versus 3-20 ng/ml in humans) (50-53). However our preliminary observations suggest that lower doses and/or intermittent dosing of mTOR inhibitors/rapalogues are also effective when combined with MEK.
inhibitors. Given the differences in toxicity observed between mice and humans, only clinical trials will reveal whether an effective, non-toxic dose can be achieved. As such, another important goal of this study was to develop a biomarker that could be used to guide dosing in the clinic.

Current clinical trial strategies involve dosing up to the Maximum Tolerated Dose of one drug, and adding the second drug to the tolerable dose when possible. However, it is not always clear how dose escalation/de-escalation affects the degree or kinetics of target inhibition or if dosing at the MTD is necessary. As such, we set out to identify a biomarker(s) that would serve as an early downstream readout of effective, combined inhibition of MEK and TORC1. While several genes were identified in these tumors, GLUT1 stood out as an important and tractable molecular change. Consistent with the documented role of GLUT1 in regulating glucose uptake, we found that $^{18}$F-FDG uptake, as measured by FDG-PET, was a reliable readout of effective, combined target inhibition in vivo. Importantly, changes in GLUT1 expression and $^{18}$F-FDG uptake occurred prior to tumor regression, supporting its role as a molecular marker of TORC1/MEK suppression rather than a consequence of tumor shrinkage. Interestingly, neither GLUT1 expression nor glucose uptake were suppressed after treatment with either rapamycin or MEK inhibitors alone. This observation differs from findings in a subset of other mTOR-driven tumor types, where HIF1α-dependent GLUT1 expression is decreased after treatment with rapamycin, as is $^{18}$F-FDG uptake (34,35). We have previously shown that neither GLUT1 nor HIF1α levels are altered in MPNSTs when treated with rapamycin, marking an important distinction between NF1-deficient tumors and these other mTOR-driven
tumors (13). Here, we provide an explanation for this difference, as simultaneous inhibition of both the mTORC1 and MEK are required to suppress GLUT1 and $^{18}$F-FDG uptake in MPNSTs. It will be interesting to determine whether inhibition of both pathways is required to alter glucose uptake in other tumors, in particular other RAS-driven tumors. Certainly, other factors, such as hexokinase activity or other members of the GLUT family, may contribute to glucose uptake in some cancers and in these instances $^{18}$F-FDG uptake might not be an effective biomarker. However our studies suggest that FDG-PET imaging represents a promising, non-invasive means of measuring combined mTORC1/MEK inhibition in vivo in these NF1-mutant tumors, which can be readily incorporated into clinical trials. Such a tool should help identify the most effective drugs, facilitate dosing, and its utility may extend beyond NF1-mutant cancers.

METHODS

Cell Lines and Reagents
S462s and LN229s were purchased from ATCC. 90-8TLs were generously provided by Dr. Eric Legius (KULeuven). The authors performed no further authentication of the cell lines. Cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with fetal bovine serum (10%) and L-glutamine. Antibodies were obtained from the following sources: Cell Signaling Technologies: pAKT (4060), AKT (9272), pERK (4370), ERK (9102), pS6 (2211), S6 (2217), p110α (4255), p110β (3011), Vinculin (4650), 4E-BP1 (9452), mTOR (7C10), Rictor (53A2), Raptor (24C12) pTSC2 (3611), TSC2 (3612) GAPDH (2118); Santa Cruz Biotechnology: p110δ (sc-7176); Trans Labs: p120 (G12920), Sigma: Actin (A2066), Alpha Diagnostics: Glut1 (GT11-A).
Torin1, A66-(S), AZD-6284, and CAL-101 were kindly provided by Nathanael Gray (Dana Farber Cancer Institute/Harvard Medical School). MK-2206 was generously provided by D. Wade Clapp (Indiana University). GDC-0941 was provided by Genentech (San Francisco, CA). PD-0325901 was a gift from Kevin Shannon (University of California, San Francisco). Rapamycin was purchased from LC Labs.

**RNAi**

Non-Targeting and PIK3CA, PIK3CB, PIK3CD, Raptor, Rictor, mTOR siRNA pools were purchased from Dharmacon (D-001810-10, L-003018-00, L-003019-00, L-006775-00, L-004107-00, L-016984-00, L-003008-00, respectively). siRNAs were transfected overnight in antibiotic free medium using RNAiMax lipofectamine from Invitrogen.

**Cellular Proliferation Studies**

Approximately 125,000 cells per well were seeded in 6-well plates. For siRNA experiments, cells were seeded 12-16 hours after transfection. 24-hours after plating, day 0 counts were taken using a hemocytometer and trypan blue exclusion. For inhibitor experiments, drug treatments were started at this time. Inhibitors were changed once daily, except for PI3K isoform experiments where drugs were replenished twice daily. Final cell counts were taken 96 hours after day 0 counts.

**Drug treatments and dosing schedule**

Animal procedures were approved by the Center for Animal and Comparative Medicine in Harvard Medical School in accordance with the NIH Guild for the Care and Use of Laboratory Animals and the Animal Welfare Act. C56/BL6 NPcis mice have been previously described (30). Mice were treated daily with rapamycin via IP injections at 5 mg/kg prepared as previously described (13). PD-0325901 was administered at 1.5
mg/kg once or twice daily (10 hours apart) by oral gavage. PD-0325901 was prepared as previously described (54). GDC-0941 was administered at 150mg/kg once daily by oral gavage. GDC-0941 was prepared as previously described (55). Compounds given in combination were administered sequentially.

**Biopsy**

Tumor biopsy was taken on mice prior to drug treatment using the wedge biopsy technique and snap-frozen. Drug treatment was started 8 hours after initial biopsy. The post-treatment biopsy was performed 3 days after treatment began. The mouse was anesthetized by isoflurane inhalation and given a local block with lidocaine and marcaine while the tumor biopsy was collected.

**Tumor volume measurements**

Mice were started on a treatment when tumor size reached 200–1000 mm$^3$. Tumor size was measured every 2–3 days by Vernier calipers. Tumor volume was calculated using the standard formula $L \times W^2 \times 0.52$. A mouse pathologist confirmed that all tumors in this study are MPNSTs.

**$^{18}$F-FDG-PET imaging and analysis**

PET/CT scans were performed on the Bioscan NanoPET/CT at the Longwood Small Animal Imaging Facility. This PET scanner is equipped with a dedicated isoflurane anesthesia system, temperature controlled platform, cardiac gating, and respiratory gating. PET scanning was performed on anesthetized animals lying motionless on a table, after Retro-orbital IV injection of 0.1 to 10 mCi of F18-FDG PET radioisotope, while being imaged with a coincidence camera. The mice were imaged after a pre-determined “washout” period (30-60 min). Individual mice were first scanned pre-treatment and then...
40 hours after the treatment regimen was initiated (see dosing schedule methods). For quantitative analysis, the standardized uptake value (SUV) normalized to body weight in the tumor was calculated using \[ \text{SUV} = \frac{\text{ACvoi (kBq/ml)}}{\text{FDGdose (MBq)/BW (kg)}} \]

where ACvoi is the average activity concentration in the tumor volume (or the maximum value); FDGdose is the dose of F18-FDG administered; and BW is the body weight. For evaluating tumors the highest SUV in the tumor was taken as the SUVmax.

**Microarray**

RNA isolated from MPNST tumor samples from NPcis mice treated for 14 hours with vehicle, rapamycin, PD-0325901, or the combination of rapamycin and PD-0325901 For all PD-0325901 treated samples, PD-0325901 was dosed a second time at 10 hours. RNA was isolated with Trizol following the manufactures protocol. RNA clean-up was then performed using Qiagen’s RNA easy kit (#74104). The Partners HealthCare Center for Personalized Genetic Medicine core facility hybridized the RNA to the Affymetrics Mouse Gene 1.0 STS. To determine genes differentially expressed in the combination treatment, a class comparison between the combination treated samples and all other samples was performed. Analysis was completed using BRB-Array tools developed by Dr. Richard Simon and the BRB-ArrayTools Development team. Thresholds were set at \( p < 0.001 \). Microarray data can be accessed in the GEO database (accession number: GSE57141 ).

**FIGURE LEGENDS**

Figure 1. p110α and mTORC1 are critical for the proliferation of *NF1*-deficient tumor cells. A) S462, 90-8TL, and LN-229 cells were transfected with pooled siRNAs
targeting *PIK3CA*, *PIK3CB*, *PIK3CD*, or non-targeting. Bar graphs represent the relative change in cell number from day 0 to 96 hours as compared to control cells transfected with the non-targeting siRNA. Data points show triplicate averages ± SD. Immunoblots depict p110α, p110β, and p110δ protein levels 72 hours after transfection with the indicated siRNA. Actin serves as a loading control. * indicates p<0.002.  

**B)** Immunoblots showing pAKT and pS6 levels in S462 cells following treatment with indicated inhibitors (4 hours, 500nM). AKT, S6, and Actin serve as controls.  

**C)** Bar graphs of S462 and 90-8TL cells treated inhibitors as specified. Numbers represent the relative change in cell number from day 0 to 96 hours as compared to vehicle treated control cells. Data points show triplicate averages ± SD. * indicates p<0.04. 

**D)** S462 and 90-8TL cells were transfected with pooled siRNAs targeting *MTOR*, *RAPTOR*, *RICTOR*, or non-targeting. Bar graphs represent the relative change in cell number from day 0 to 96 hours as compared to control cells transfected with the non-targeting siRNA. Data points show triplicate averages ± SD. Immunoblots show mTOR, Raptor, Rictor, pAKT, and pS6 levels 72 hours after transfection with the indicated siRNA. AKT, S6, and Actin levels serve as controls. * indicates p<0.02. 

**E)** S462 cells were treated with the rapamycin (Rap) at 100nM, Torin1 at 250nM or MK-2206 (concentration indicated). Bar graph represents the relative change in cell number from day 0 to 96 hours as compared to vehicle treated control cells. Data points show triplicate averages ± SD. Immunoblots show pAKT T308, pAKT S473, pTSC2 T1462, pS6, and 4E-BP1 levels in the presence of the specified inhibitors. AKT, TSC2, S6, and actin serve as controls. * indicates p<0.0001. 

**F)** S462 cells treated with either rapamycin at 100nM, MK-2206 at 5 μM, or both drugs together. Bar graphs represent the relative change in cell number from day 0
to 96 hours as compared to vehicle treated control cells. Data points show triplicate averages ± SD.

**Figure 2. Therapeutic effects of PI3K and MEK pathway inhibitors in vivo.** A) Waterfall plot depicting change in tumor volume in *NP cis* mice after 10 days of treatment with vehicle (black), GDC-0941 (blue), or rapamycin (green). The left y-axis indicates the log2 of the fold change in volume after 10 days. The right y-axis indicates the percent change in tumor volume relative to day 0. B) pAKT/pS6/4E-BP1 immunoblots of tissue from animals exposed to GDC-0941 or rapamycin for the indicated amount of time. AKT, S6, and vinculin serve as controls. C) Waterfall plot depicting change in tumor volume after 10 days of treatment with PD-0325901 (yellow) or rapamycin and PD-0325901 in combination (purple). Vehicle and rapamycin (gray) are reprinted from Figure 2A for reference. The left y-axis indicates the log2 of the fold change in volume after 10 days. The right y-axis indicates the percent change in tumor volume relative to day 0. D) Immunoblots showing pERK levels in tissue after treatment with PD-0325901 once daily (top) or twice daily (bottom). Hours indicate the number of hours from initial treatment. Representative samples from three biological replicates are shown. Vinculin and ERK serve as controls. E) Waterfall plot depicting change in tumor volume after 10 days of treatment with PD-0325901 twice daily or PD-0325901 twice daily in combination with rapamycin. The left y-axis indicates the log2 of the fold change in tumor volume relative to day 0, and the right y-axis indicates the percent change in tumor volume.
Figure 3. GLUT1 is an early biomarker of effective combined MEK/mTORC1 inhibition. A) Microarray analysis of mouse tumors 14 hours after treatment with vehicle, rapamycin, PD-0325901 (PD) or both rapamycin and PD-0325901 (Rap/PD). Heat map depicts the uniquely upregulated genes (dark blue) or downregulated genes (light blue) from tumors in mice treated with Rap/PD as compared to all other groups reaching a significance level of p=0.001. The arrow denotes Slc2a1, highlighted in red, as one gene of particular interest within this signature. B) Immunoblot of pERK and 4E-BP1 levels in individual tumors as described in 3A. ERK and GAPDH serve as a control. C) Quantitative PCR showing GLUT1 transcript levels in individual tumors described in 3A. D) Immunoblot showing GLUT1 levels in a pre-treatment biopsy sample, and in the same tumor after treatment with PD-0325901 (twice daily) and rapamycin. p120 serves as a control.

Figure 4. 18F-FDG uptake is a non-invasive biomarker of combined MEK/ mTORC1 inhibition. A) Representative images of FDG-PET scans of animals treated with vehicle, PD-0325901, rapamycin, or both (Rap/PD). PD-0325901 was dosed twice daily. Baseline scans are shown at left (Pre-) and the right image shows the same view of the same animal 40-hours after treatment with the indicated compound (Post-). The arrow indicates the MPNST. Scale bar shows relative 18F-FDG uptake, with low uptake in blue and highest uptake in white. B) The 18F-FDG uptake by tumors was quantified using SUVmax, and the log2 of the fold change of this number was calculated to indicate the change in 18F-FDG uptake 40 hours after treatment relative to baseline for each animal. The change in combination treated animals (Rap/PD) is compared to monotherapy and
vehicle treated animals (controls). The y-axis indicates the log2 of the fold change in SUVmax relative to baseline. **C)** Representative images of FDG-PET scans of animals treated with 100% PD-0324901/rapamycin, 50%PD-0325901 rapamycin, or 25% PD-0325901/rapamycin. The left image (Pre-) shows the baseline scan for each animal and the right (Post-) shows the scan 40 hours after treatment with the indicated dose. Again, the tumors are indicated with arrows. Scale bar shows relative FDG uptake, with low uptake in blue and highest uptake in white. **D)** On the left, a waterfall plot depicting the log2 fold change of SUVmax, a quantification of tumor FDG-PET activity, of selected tumors at 40 hours after treatment with PD-0325901 (25%, 50% or 100% of the dose) and rapamycin. On the right, a waterfall plot depicting the log2 of fold change in tumor volume after 10 days of the same mice. Individual tumors are graphed in the same order on each plot. **E)** Regression analysis of nine combination treated mice (100% n=3, 50% n=3, 25% n=3). The x-axis represents the log2 of fold change in tumor volume at 10 days and the y-axis represents the log2 of fold change in SUVmax levels after 40 hours of treatment. Both numbers are relative to day 0 measurements. The line represents the best-fit linear correlation, and the Pearson coefficient (r) was calculated.

**Acknowledgements**

We would like to thank Haley Goodwill, John Frangioni, and the Longwood Small Animal Imaging facility at Beth Israel Hospital for performing the $^{18}$F-FDG PET imaging studies. We also thank Roderick T. Bronson for histologic confirmation of all MPNSTs.

**REFERENCES**


Figure 2

A. Log2 Fold of Tumor Growth (Day 10)

B. GDC-0941

<table>
<thead>
<tr>
<th>Hours</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>4</th>
<th>12</th>
</tr>
</thead>
<tbody>
<tr>
<td>pAKT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AKT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pS6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vinculin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4E-BP1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Rapamycin

<table>
<thead>
<tr>
<th>Hours</th>
<th>0</th>
<th>2</th>
<th>6</th>
<th>12</th>
<th>18</th>
</tr>
</thead>
<tbody>
<tr>
<td>pAKT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AKT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pS6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vinculin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4E-BP1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C. Log2 Fold of Tumor Growth (Day 10)

D. Once Daily Treatment

<table>
<thead>
<tr>
<th>Hours</th>
<th>0</th>
<th>2</th>
<th>4</th>
<th>10</th>
<th>14</th>
<th>24</th>
</tr>
</thead>
<tbody>
<tr>
<td>pERK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ERK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vinculin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Twice Daily Treatment

<table>
<thead>
<tr>
<th>Hours</th>
<th>0</th>
<th>2</th>
<th>4</th>
<th>14</th>
<th>16</th>
<th>24</th>
</tr>
</thead>
<tbody>
<tr>
<td>pERK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ERK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vinculin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 3

A. Heatmap of gene expression levels in different treatment groups. The heatmaps are color-coded to represent the expression levels of various genes, with blue indicating lower expression and red indicating higher expression.

B. Western blot analysis showing protein levels of 4E-BP1, pERK, ERK, and GAPDH in different treatment groups. The blots demonstrate the relative expression levels of these proteins under different conditions.

C. Bar graph showing relative expression levels of SLC2A1 in the Vehicle, PD, Rap, and Rap/PD groups. The graph includes error bars to indicate the standard deviation.

D. Western blot analysis of GLUT1 and p120 proteins before (Pre-) and after (Post-) treatment with different agents.
CANCER DISCOVERY

Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers

Clare F Malone, Jody A Fromm, Ophelia Maertens, et al.

Cancer Discovery Published OnlineFirst June 9, 2014.

Updated version
Access the most recent version of this article at:
doi:10.1158/2159-8290.CD-14-0159

Supplementary Material
Access the most recent supplemental material at:
http://cancerdiscovery.aacrjournals.org/content/suppl/2014/06/10/2159-8290.CD-14-0159.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.